In the case of severe renal insufficiency, Ajalorin orodispersible tablets should be used with caution (see Pharmacology: Pharmacokinetics under Actions).
Desloratadine should be administered with caution in patients with medical or familial history of seizures, and mainly young children, being more susceptible to develop new seizures under desloratadine treatment. Healthcare providers may consider discontinuing desloratadine in patients who experience a seizure while on treatment.
This product contains aspartame. It may be harmful for people with phenylketonuria.
Effects on Ability to drive and use Machine: Desloratadine has no or negligible influence on the ability to drive and use machines based on clinical trials.
Patients should be informed that most people do not experience drowsiness. Nevertheless, as there is individual variation in response to all medical products, it is recommended that patients are advised not to engage in activities requiring mental alertness, such as driving a car or using machines, until they have established their own response to the medicinal product.